<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>JETREA- ocriplasmin injection, solution </strong><br>ThromboGenics Inc.<br></p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div class="HighlightsDisclaimer"><span class="Bold">These highlights do not include all the information needed to use JETREA safely and effectively. See full prescribing information for JETREA
			<br>JETREA<span class="Sup">®</span> (ocriplasmin) Intravitreal Injection, 2.5 mg/mL 
			<br>Initial U.S. Approval: 2012
		</span></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>RECENT MAJOR CHANGES</span></h1>
<div><p class="Highlighta">Postmarketing Experience (<a href="#YS0063">6.3</a>)
                         </p></div>
</div>
<div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div><p class="Highlighta">JETREA is a proteolytic enzyme indicated for the treatment of symptomatic vitreomacular <span class="product-label-link" type="condition" conceptid="4175338" conceptname="Adhesion">adhesion</span>. <a href="#rpm010390682b8-72c4-11e1-b0c4-0800200c9a66">(1)</a> </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div><ul>
<li>Must dilute before use. <a href="#rpm021390682ba-72c4-11e1-b0c4-0800200c9a66">(2.1)</a>
</li>
<li>For single use ophthalmic intravitreal injection only. <a href="#rpm021390682ba-72c4-11e1-b0c4-0800200c9a66">(2.1)</a>
</li>
<li>The recommended dose is 0.125 mg (0.1 mL of the diluted solution) administered by intravitreal injection to the affected eye once as a single dose. <a href="#rpm022390682bb-72c4-11e1-b0c4-0800200c9a66">(2.2)</a>
</li>
</ul></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div><p class="Highlighta">Single-use glass vial containing JETREA 0.5 mg in 0.2 mL solution for intravitreal injection (2.5 mg/mL). <a href="#rpm030390682bf-72c4-11e1-b0c4-0800200c9a66">(3)</a> </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div><p class="Highlighta">None. <a href="#rpm040390682c0-72c4-11e1-b0c4-0800200c9a66">(4)</a> </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div><ul>
<li>Decreases in vision due to progression of the condition with traction may occur requiring <span class="product-label-link" type="condition" conceptid="4121697" conceptname="Surgery">surgical intervention</span>. Patients should be monitored and instructed to report any symptoms without delay. <a href="#rpm051390682c3-72c4-11e1-b0c4-0800200c9a66">(5.1)</a>
</li>
<li>Intravitreal injection procedure associated effects (intraocular <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span>/<span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>, <span class="product-label-link" type="condition" conceptid="433778" conceptname="Orbital hemorrhage">intraocular hemorrhage</span> and increased IOP) may occur following an intravitreal injection. Patients should be monitored and instructed to report any symptoms without delay. <a href="#rpm052390682c5-72c4-11e1-b0c4-0800200c9a66">(5.2)</a>
</li>
<li>Potential for lens <span class="product-label-link" type="condition" conceptid="72468" conceptname="Open dislocation of jaw">subluxation</span>.  <a href="#rpm053390682c6-72c4-11e1-b0c4-0800200c9a66">(5.3)</a>
</li>
</ul></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div>
<ul><li>The most commonly reported reactions (≥ 5%) in patients treated with JETREA were <span class="product-label-link" type="condition" conceptid="4034681" conceptname="Vitreous floaters">vitreous floaters</span>, <span class="product-label-link" type="condition" conceptid="378756" conceptname="Conjunctival hemorrhage">conjunctival hemorrhage</span>, <span class="product-label-link" type="condition" conceptid="379031" conceptname="Pain in eye">eye pain</span>, <span class="product-label-link" type="condition" conceptid="4206763" conceptname="Photopsia">photopsia</span>, <span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">blurred vision</span>, <span class="product-label-link" type="condition" conceptid="4338894" conceptname="Macular hole">macular hole</span>, reduced visual acuity, <span class="product-label-link" type="condition" conceptid="373786" conceptname="Abnormal vision">visual impairment</span>, and <span class="product-label-link" type="condition" conceptid="372903" conceptname="Retinal edema">retinal edema</span>. <a href="#rpm061390682cb-72c4-11e1-b0c4-0800200c9a66">(6.1)</a>
</li></ul>
<p class="Highlighta"><span class="Bold">To report SUSPECTED ADVERSE REACTIONS, contact ThromboGenics Inc. at 1-855-253-7396 or FDA at 1-800-FDA-1088 or <span class="Italics Underline">www.fda.gov/medwatch</span>.</span> </p>
<br>
</div>
<div></div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
</div>
<div></div>
<div><div></div></div>
<div></div>
<div></div>
<div></div>
<p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION.</p>
<p class="HighlightsRevision">Revised: 9/2015</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-1" class="toc">1.  INDICATIONS AND USAGE</a></h1>
<h1><a href="#section-2" class="toc">2.  DOSAGE AND ADMINISTRATION</a></h1>
<h2><a href="#section-2.1" class="toc">2.1. General Dosing Information</a></h2>
<h2><a href="#section-2.2" class="toc">2.2. Dosing</a></h2>
<h2><a href="#section-2.3" class="toc">2.3. Preparation for Administration</a></h2>
<h2><a href="#section-2.4" class="toc">2.4. Administration and Monitoring</a></h2>
<h1><a href="#section-3" class="toc">3.  DOSAGE FORMS AND STRENGTHS</a></h1>
<h1><a href="#section-4" class="toc">4.  CONTRAINDICATIONS</a></h1>
<h1><a href="#section-5" class="toc">5.  WARNINGS AND PRECAUTIONS</a></h1>
<h2><a href="#section-5.1" class="toc">5.1. Decreased Vision</a></h2>
<h2><a href="#section-5.2" class="toc">5.2. Intravitreal Injection Procedure Associated Effects</a></h2>
<h2><a href="#section-5.3" class="toc">5.3. Potential for Lens <span class="product-label-link" type="condition" conceptid="72468" conceptname="Open dislocation of jaw">Subluxation</span></a></h2>
<h2><a href="#section-5.4" class="toc">5.4. Retinal Breaks</a></h2>
<h2><a href="#section-5.5" class="toc">5.5. <span class="product-label-link" type="condition" conceptid="4092111" conceptname="Chromatopsia">Dyschromatopsia</span></a></h2>
<h1><a href="#section-6" class="toc">6.  ADVERSE REACTIONS</a></h1>
<h2><a href="#section-6.1" class="toc">6.1. Clinical Trials Experience</a></h2>
<h2><a href="#section-6.2" class="toc">6.2. Immunogenicity</a></h2>
<h2><a href="#section-6.3" class="toc">6.3.	Postmarketing Experience</a></h2>
<h1><a href="#section-7" class="toc">8.  USE IN SPECIFIC POPULATIONS</a></h1>
<h2><a href="#section-7.1" class="toc">8.1.  Pregnancy</a></h2>
<h2><a href="#section-7.2" class="toc">8.3. Nursing Mothers</a></h2>
<h2><a href="#section-7.3" class="toc">8.4.  Pediatric Use</a></h2>
<h2><a href="#section-7.4" class="toc">8.5.  Geriatric Use</a></h2>
<h1><a href="#section-8" class="toc">10.  OVERDOSAGE</a></h1>
<h1><a href="#section-9" class="toc">11.  DESCRIPTION</a></h1>
<h1><a href="#section-10" class="toc">12.  CLINICAL PHARMACOLOGY</a></h1>
<h2><a href="#section-10.1" class="toc">12.1.  Mechanism of Action</a></h2>
<h2><a href="#section-10.2" class="toc">12.3.  Pharmacokinetics</a></h2>
<h1><a href="#section-11" class="toc">13.  NONCLINICAL TOXICOLOGY</a></h1>
<h2><a href="#section-11.1" class="toc">13.1.  Carcinogenesis, Mutagenesis, Impairment of Fertility</a></h2>
<h2><a href="#section-11.2" class="toc">13.2.  Animal Toxicology and/or Pharmacology</a></h2>
<h1><a href="#section-12" class="toc">14.  CLINICAL STUDIES</a></h1>
<h1><a href="#section-13" class="toc">16.  HOW SUPPLIED/STORAGE AND HANDLING</a></h1>
<h1><a href="#section-14" class="toc">17.  PATIENT COUNSELING INFORMATION</a></h1>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="rpm010390682b8-72c4-11e1-b0c4-0800200c9a66"></a><a name="section-1"></a><p></p>
<h1>1.  INDICATIONS AND USAGE</h1>
<p class="First">JETREA<span class="Sup">®</span> is a proteolytic enzyme indicated for the treatment of symptomatic vitreomacular <span class="product-label-link" type="condition" conceptid="4175338" conceptname="Adhesion">adhesion</span>.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="rpm020390682b9-72c4-11e1-b0c4-0800200c9a66"></a><a name="section-2"></a><p></p>
<h1>2.  DOSAGE AND ADMINISTRATION</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="rpm021390682ba-72c4-11e1-b0c4-0800200c9a66"></a><a name="section-2.1"></a><p></p>
<h2>2.1. General Dosing Information</h2>
<p class="First">Must be diluted before use. For single-use ophthalmic intravitreal injection only. JETREA must only be administered by a qualified physician.</p>
<br>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="rpm022390682bb-72c4-11e1-b0c4-0800200c9a66"></a><a name="section-2.2"></a><p></p>
<h2>2.2. Dosing</h2>
<p class="First">The recommended dose is 0.125 mg (0.1 mL of the diluted solution) administered by intravitreal injection to the affected eye once as a single dose. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="rpm023390682bc-72c4-11e1-b0c4-0800200c9a66"></a><a name="section-2.3"></a><p></p>
<h2>2.3. Preparation for Administration</h2>
<p class="First">To prepare JETREA for intravitreal injection, adhere to the following instructions:</p>
<ol>
<li>
<p class="First">Remove the vial (2.5 mg/mL corresponding to 0.5 mg ocriplasmin) from the freezer and allow to thaw at room temperature (within a few minutes).
										</p>
<br>
</li>
<li>
<p class="First">Once completely thawed, remove the protective polypropylene flip-off cap from the vial <span class="Bold">(see Figure 1)</span>.
										</p>
<br><p><span class="Bold">Figure 1:</span></p>
<p><img alt="take cap off vial" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=390682b7-72c4-11e1-b0c4-0800200c9a66&amp;name=jetrea-figure-1.jpg"></p>
</li>
<li>
<p class="First">The top of the vial should be disinfected with an alcohol wipe <span class="Bold">(see Figure 2)</span>.</p>
<br><p><span class="Bold">Figure 2:</span></p>
<p><img alt="wipe vial" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=390682b7-72c4-11e1-b0c4-0800200c9a66&amp;name=jetrea-figure-2.jpg"></p>
</li>
<li>
<p class="First">Using aseptic technique, add 0.2 mL of 0.9% w/v Sodium Chloride Injection, USP (sterile, preservative-free) into the JETREA vial <span class="Bold">(see Figure 3)</span> and gently swirl the vial until the solutions are mixed <span class="Bold">(see Figure 4)</span>.</p>
<br><p><span class="Bold">Figure 3:</span></p>
<p><img alt="add NaCl to vial" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=390682b7-72c4-11e1-b0c4-0800200c9a66&amp;name=jetrea-figure-3.jpg"></p>
<p><span class="Bold">Figure 4:</span></p>
<p><img alt="swirl vial" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=390682b7-72c4-11e1-b0c4-0800200c9a66&amp;name=jetrea-figure-4.jpg"></p>
</li>
<li>
<p class="First">Visually inspect the vial for particulate matter. Only a clear, colorless solution without visible particles should be used.</p>
<br>
</li>
<li>
<p class="First">Using aseptic technique, withdraw all of the diluted solution using a sterile #19 gauge needle (slightly tilt the vial to ease withdrawal) and discard the needle after withdrawal of the vial contents <span class="Bold">(see Figure 5)</span>. Do not use this needle for the intravitreal injection.</p>
<br><p><span class="Bold">Figure 5:</span></p>
<p><img alt="withdraw solution from vial" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=390682b7-72c4-11e1-b0c4-0800200c9a66&amp;name=jetrea-figure-5.jpg"></p>
</li>
<li>
<p class="First">Replace the needle with a sterile #30 gauge needle, carefully expel the air bubbles and excess drug from the syringe and adjust the dose to the 0.1 mL mark on the syringe (corresponding to 0.125 mg ocriplasmin) <span class="Bold">(see Figure 6)</span>.</p>
<br><p><span class="Bold">Figure 6:</span></p>
<p><img alt="adjust volume to 0.1 mL" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=390682b7-72c4-11e1-b0c4-0800200c9a66&amp;name=jetrea-figure-6.jpg"></p>
</li>
<li>
<p class="First">THE SOLUTION SHOULD BE USED IMMEDIATELY AS IT CONTAINS NO PRESERVATIVES.</p>
<br>
</li>
<li><p class="First">Discard the vial and any unused portion of the diluted solution after single use.</p></li>
</ol>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="rpm024390682be-72c4-11e1-b0c4-0800200c9a66"></a><a name="section-2.4"></a><p></p>
<h2>2.4. Administration and Monitoring</h2>
<p class="First">The intravitreal injection procedure should be carried out under controlled aseptic conditions, which include the use of sterile gloves, a sterile drape and a sterile eyelid speculum (or equivalent). Adequate anesthesia and a broad spectrum microbiocide should be administered according to standard medical practice. </p>
<p>The injection needle should be inserted 3.5 - 4.0 mm posterior to the limbus aiming towards the center of the vitreous cavity, avoiding the horizontal meridian. The injection volume of 0.1 mL is then delivered into the mid-vitreous.</p>
<p>Immediately following the intravitreal injection, patients should be monitored for elevation in intraocular pressure. Appropriate monitoring may consist of a check for perfusion of the optic nerve head or tonometry. If required, a sterile paracentesis needle should be available.</p>
<p>Following intravitreal injection, patients should be instructed to report any symptoms suggestive of <span class="product-label-link" type="condition" conceptid="438411" conceptname="Endophthalmitis">endophthalmitis</span> or <span class="product-label-link" type="condition" conceptid="378414" conceptname="Retinal detachment">retinal detachment</span> (e.g., <span class="product-label-link" type="condition" conceptid="379031" conceptname="Pain in eye">eye pain</span>, <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">redness</span> of the eye, <span class="product-label-link" type="condition" conceptid="4260194" conceptname="Photophobia">photophobia</span>, blurred or decreased vision) without delay <span class="Italics">[see Patient Counseling Information (</span><a href="#rpm1703906a9ca-72c4-11e1-b0c4-0800200c9a66">17</a><span class="Italics">)]</span>.</p>
<p>Each vial should only be used to provide a single injection for the treatment of a single eye. If the contralateral eye requires treatment, a new vial should be used and the sterile field, syringe, gloves, drapes, eyelid speculum, and injection needles should be changed before JETREA is administered to the other eye, however, treatment with JETREA in the other eye is not recommended within 7 days of the initial injection in order to monitor the post-injection course including the potential for decreased vision in the injected eye.</p>
<p>Repeated administration of JETREA in the same eye is not recommended <span class="Italics">[see Nonclinical Toxicology <a href="#rpm1323906a9c5-72c4-11e1-b0c4-0800200c9a66">(13.2)</a>]</span>.</p>
<p>After injection, any unused product must be discarded.</p>
<p>No special dosage modification is required for any of the populations that have been studied (e.g. gender, elderly).</p>
</div>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="rpm030390682bf-72c4-11e1-b0c4-0800200c9a66"></a><a name="section-3"></a><p></p>
<h1>3.  DOSAGE FORMS AND STRENGTHS</h1>
<p class="First">Single-use glass vial containing JETREA 0.5 mg in 0.2 mL solution for intravitreal injection (2.5 mg/mL).</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="rpm040390682c0-72c4-11e1-b0c4-0800200c9a66"></a><a name="section-4"></a><p></p>
<h1>4.  CONTRAINDICATIONS</h1>
<p class="First">None</p>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="rpm050390682c4-72c4-11e1-b0c4-0800200c9a66"></a><a name="section-5"></a><p></p>
<h1>5.  WARNINGS AND PRECAUTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="rpm051390682c3-72c4-11e1-b0c4-0800200c9a66"></a><a name="section-5.1"></a><p></p>
<h2>5.1. Decreased Vision</h2>
<p class="First">A decrease of ≥ 3 line of best corrected visual acuity (BCVA) was experienced by 5.6% of patients treated with JETREA and 3.2% of patients treated with vehicle in the controlled trials <span class="Italics">[see Clinical Studies <a href="#rpm1403906a9c6-72c4-11e1-b0c4-0800200c9a66">(14)</a>]</span>.</p>
<p>The majority of these decreases in vision were due to progression of the condition with traction and many required <span class="product-label-link" type="condition" conceptid="4121697" conceptname="Surgery">surgical intervention</span>. Patients should be monitored appropriately <span class="Italics">[see Dosage and Administration <a href="#rpm024390682be-72c4-11e1-b0c4-0800200c9a66">(2.4)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="rpm052390682c5-72c4-11e1-b0c4-0800200c9a66"></a><a name="section-5.2"></a><p></p>
<h2>5.2. Intravitreal Injection Procedure Associated Effects</h2>
<p class="First">Intravitreal injections are associated with intraocular <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span> / <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>, <span class="product-label-link" type="condition" conceptid="433778" conceptname="Orbital hemorrhage">intraocular hemorrhage</span> and <span class="product-label-link" type="condition" conceptid="4011560" conceptname="Raised intraocular pressure">increased intraocular pressure</span> (IOP). In the controlled trials, intraocular <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span> occurred in 7.1% of patients injected with JETREA vs. 3.7% of patients injected with vehicle. Most of the post-injection intraocular <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span> events were mild and transient. <span class="product-label-link" type="condition" conceptid="433778" conceptname="Orbital hemorrhage">Intraocular hemorrhage</span> occurred in 2.4% vs. 3.7% of patients injected with JETREA vs. vehicle, respectively. <span class="product-label-link" type="condition" conceptid="4011560" conceptname="Raised intraocular pressure">Increased intraocular pressure</span> occurred in 4.1% vs. 5.3% of patients injected with JETREA vs. vehicle, respectively.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="rpm053390682c6-72c4-11e1-b0c4-0800200c9a66"></a><a name="section-5.3"></a><p></p>
<h2>5.3. Potential for Lens <span class="product-label-link" type="condition" conceptid="72468" conceptname="Open dislocation of jaw">Subluxation</span></h2>
<p class="First">One case of lens <span class="product-label-link" type="condition" conceptid="72468" conceptname="Open dislocation of jaw">subluxation</span> was reported in a premature infant  who received an intravitreal injection of 0.175 mg (1.4 times higher than the recommended dose) <span class="Italics">[see Pediatric Use <a href="#rpm084390682d1-72c4-11e1-b0c4-0800200c9a66">(8.4)</a>]</span>. Lens <span class="product-label-link" type="condition" conceptid="72468" conceptname="Open dislocation of jaw">subluxation</span> was observed in three animal species (monkey, rabbit, minipig) following a single intravitreal injection that achieved vitreous concentrations of ocriplasmin 1.4 times higher than achieved with the recommended treatment dose. Administration of a second intravitreal dose in monkeys, 28 days apart, produced lens <span class="product-label-link" type="condition" conceptid="72468" conceptname="Open dislocation of jaw">subluxation</span> in 100% of the treated eyes <span class="Italics">[see Nonclinical Toxicology <a href="#rpm1323906a9c5-72c4-11e1-b0c4-0800200c9a66">(13.2)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="rpm054390682c7-72c4-11e1-b0c4-0800200c9a66"></a><a name="section-5.4"></a><p></p>
<h2>5.4. Retinal Breaks</h2>
<p class="First">In the controlled trials, the incidence of <span class="product-label-link" type="condition" conceptid="378414" conceptname="Retinal detachment">retinal detachment</span> was 0.9% in the JETREA group and 1.6% in the vehicle group, while the incidence of <span class="product-label-link" type="condition" conceptid="4317972" conceptname="Retinal tear">retinal tear</span> (without detachment) was 1.1% in the JETREA group and 2.7% in the vehicle group. Most of these events occurred during or after vitrectomy in both groups. The incidence of <span class="product-label-link" type="condition" conceptid="378414" conceptname="Retinal detachment">retinal detachment</span> that occurred pre-vitrectomy was 0.4% in the JETREA group and none in the vehicle group, while the incidence of <span class="product-label-link" type="condition" conceptid="4317972" conceptname="Retinal tear">retinal tear</span> (without detachment) that occurred pre-vitrectomy was none in the JETREA group and 0.5% in the vehicle group.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="rpm055390682c9-72c4-11e1-b0c4-0800200c9a66"></a><a name="section-5.5"></a><p></p>
<h2>5.5. <span class="product-label-link" type="condition" conceptid="4092111" conceptname="Chromatopsia">Dyschromatopsia</span></h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="4092111" conceptname="Chromatopsia">Dyschromatopsia</span> (generally described as yellowish vision) was reported in 2% of all patients injected with JETREA. In approximately half of these <span class="product-label-link" type="condition" conceptid="4092111" conceptname="Chromatopsia">dyschromatopsia</span> cases there were also electroretinographic (ERG) changes reported (a- and b-wave amplitude decrease).</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="rpm060390682ca-72c4-11e1-b0c4-0800200c9a66"></a><a name="section-6"></a><p></p>
<h1>6.  ADVERSE REACTIONS</h1>
<p class="First">The following adverse reactions are described below and elsewhere in the labeling:</p>
<br><ul>
<li>  Decreased Vision <span class="Italics">[see Warnings and Precautions <a href="#rpm051390682c3-72c4-11e1-b0c4-0800200c9a66">(5.1)</a>]</span>
</li>
<li>  Intravitreal Injection Procedure Associated Effects <span class="Italics">[see Warnings and Precautions <a href="#rpm052390682c5-72c4-11e1-b0c4-0800200c9a66">(5.2)</a> and Dosage and Administration <a href="#rpm024390682be-72c4-11e1-b0c4-0800200c9a66">(2.4)</a>]</span>
</li>
<li>  Potential for Lens <span class="product-label-link" type="condition" conceptid="72468" conceptname="Open dislocation of jaw">Subluxation</span> <span class="Italics">[see Warnings and Precautions <a href="#rpm053390682c6-72c4-11e1-b0c4-0800200c9a66">(5.3)</a>]</span>
</li>
<li>  Retinal Breaks <span class="Italics">[see Warnings and Precautions <a href="#rpm054390682c7-72c4-11e1-b0c4-0800200c9a66">(5.4)</a> and Dosage and Administration <a href="#rpm024390682be-72c4-11e1-b0c4-0800200c9a66">(2.4)</a>]</span>
</li>
</ul>
<div class="Section" data-sectionCode="42229-5">
<a name="rpm061390682cb-72c4-11e1-b0c4-0800200c9a66"></a><a name="section-6.1"></a><p></p>
<h2>6.1. Clinical Trials Experience</h2>
<p class="First">Because clinical trials are conducted under widely varying conditions, adverse reaction rates in one clinical trial of a drug cannot be directly compared with rates in the clinical trials of the same or another drug and may not reflect the rates observed in practice.</p>
<p>Approximately 800 patients have been treated with an intravitreal injection of JETREA. Of these, 465 patients received an intravitreal injection of ocriplasmin 0.125 mg (187 patients received vehicle) in the 2 vehicle-controlled studies (Study 1 and Study 2).</p>
<p>The most common adverse reactions (incidence 5% - 20% listed in descending order of frequency) in the vehicle-controlled clinical studies were: <span class="product-label-link" type="condition" conceptid="4034681" conceptname="Vitreous floaters">vitreous floaters</span>, <span class="product-label-link" type="condition" conceptid="378756" conceptname="Conjunctival hemorrhage">conjunctival hemorrhage</span>, <span class="product-label-link" type="condition" conceptid="379031" conceptname="Pain in eye">eye pain</span>, <span class="product-label-link" type="condition" conceptid="4206763" conceptname="Photopsia">photopsia</span>, <span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">blurred vision</span>, <span class="product-label-link" type="condition" conceptid="4338894" conceptname="Macular hole">macular hole</span>, reduced visual acuity, <span class="product-label-link" type="condition" conceptid="373786" conceptname="Abnormal vision">visual impairment</span>, and  <span class="product-label-link" type="condition" conceptid="372903" conceptname="Retinal edema">retinal edema</span>.</p>
<p>Less common adverse reactions observed in the studies at a frequency of 2% - &lt; 5% in patients treated with JETREA included <span class="product-label-link" type="condition" conceptid="4290333" conceptname="Macular retinal edema">macular edema</span>, <span class="product-label-link" type="condition" conceptid="4011560" conceptname="Raised intraocular pressure">increased intraocular pressure</span>, <span class="product-label-link" type="condition" conceptid="4081011" conceptname="Anterior chamber cells">anterior chamber cell</span>, <span class="product-label-link" type="condition" conceptid="4260194" conceptname="Photophobia">photophobia</span>, <span class="product-label-link" type="condition" conceptid="4202518" conceptname="Vitreous detachment">vitreous detachment</span>, <span class="product-label-link" type="condition" conceptid="372912" conceptname="Visual discomfort">ocular discomfort</span>, <span class="product-label-link" type="condition" conceptid="4274964" conceptname="Iritis">iritis</span>, <span class="product-label-link" type="condition" conceptid="375545" conceptname="Cataract">cataract</span>, <span class="product-label-link" type="condition" conceptid="373204" conceptname="Conjunctival xerosis">dry eye</span>, <span class="product-label-link" type="condition" conceptid="380707" conceptname="Metamorphopsia">metamorphopsia</span>, <span class="product-label-link" type="condition" conceptid="377283" conceptname="Conjunctival hyperemia">conjunctival hyperemia</span>, and <span class="product-label-link" type="condition" conceptid="4090255" conceptname="Retinal drusen">retinal degeneration</span>.</p>
<p><span class="product-label-link" type="condition" conceptid="4092111" conceptname="Chromatopsia">Dyschromatopsia</span> was reported in 2% of patients injected with JETREA, with the majority of cases reported from two uncontrolled clinical studies. In approximately half of these <span class="product-label-link" type="condition" conceptid="4092111" conceptname="Chromatopsia">dyschromatopsia</span> cases there were also electroretinographic (ERG) changes reported (a- and b-wave amplitude decrease).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="rpm062390682cc-72c4-11e1-b0c4-0800200c9a66"></a><a name="section-6.2"></a><p></p>
<h2>6.2. Immunogenicity</h2>
<p class="First">As with all therapeutic proteins, there is potential for immunogenicity. Immunogenicity for this product has not been evaluated.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="YS0063"></a><a name="section-6.3"></a><p></p>
<h2>6.3.	Postmarketing Experience</h2>
<p class="First">The following adverse reactions have been identified during post-approval use of JETREA. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.</p>
<ul>
<li><span class="product-label-link" type="condition" conceptid="4105178" conceptname="Cystoid macular edema">Cystoid macular edema</span></li>
<li><span class="product-label-link" type="condition" conceptid="374037" conceptname="Night blindness">Night blindness</span></li>
<li>Pupillary reflex impaired</li>
<li>Visual symptoms perceived in the contralateral eye or bilaterally </li>
</ul>
</div>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="rpm080390682ce-72c4-11e1-b0c4-0800200c9a66"></a><a name="section-7"></a><p></p>
<h1>8.  USE IN SPECIFIC POPULATIONS</h1>
<div class="Section" data-sectionCode="42228-7">
<a name="rpm081390682cf-72c4-11e1-b0c4-0800200c9a66"></a><a name="section-7.1"></a><p></p>
<h2>8.1.  Pregnancy</h2>
<p class="First"><span class="Bold">Teratogenic Effects</span></p>
<p>Pregnancy Category C. Animal reproduction studies have not been conducted with ocriplasmin. There are no adequate and well-controlled studies of ocriplasmin in pregnant women. It is not known whether ocriplasmin can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. The systemic exposure to ocriplasmin is expected to be low after intravitreal injection of a single 0.125 mg dose. Assuming 100% systemic absorption (and a plasma volume of 2700 mL), the estimated plasma concentration is 46 ng/mL. JETREA should be given to a pregnant woman only if clearly needed.</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="rpm083390682d0-72c4-11e1-b0c4-0800200c9a66"></a><a name="section-7.2"></a><p></p>
<h2>8.3. Nursing Mothers</h2>
<p class="First">It is not known whether ocriplasmin is excreted in human milk. Because many drugs are excreted in human milk, and because the potential for absorption and harm to infant growth and development exists, caution should be exercised when JETREA is administered to a nursing woman. </p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="rpm084390682d1-72c4-11e1-b0c4-0800200c9a66"></a><a name="section-7.3"></a><p></p>
<h2>8.4.  Pediatric Use</h2>
<p class="First">The use of JETREA in pediatric patients is not recommended. A single center, randomized, placebo controlled, double masked clinical study to investigate the safety and efficacy of a single intravitreal injection of 0.175 mg ocriplasmin in pediatric subjects as an adjunct to vitrectomy was conducted in 24 eyes of 22 patients. There were no statistical or clinical differences between groups for the induction of total macular PVD, any of the secondary endpoints or adverse events.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="rpm085390682d2-72c4-11e1-b0c4-0800200c9a66"></a><a name="section-7.4"></a><p></p>
<h2>8.5.  Geriatric Use</h2>
<p class="First">In the clinical studies, 384 and 145 patients were ≥ 65 years and of these 192 and 73 patients were ≥ 75 years in the JETREA and vehicle groups respectively. No significant differences in efficacy or safety were seen with increasing age in these studies.</p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="rpm100390682d5-72c4-11e1-b0c4-0800200c9a66"></a><a name="section-8"></a><p></p>
<h1>10.  OVERDOSAGE</h1>
<p class="First">The clinical data on the effects of JETREA <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> are limited. One case of accidental <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> of 0.250 mg ocriplasmin (twice the recommended dose) was reported to be associated with <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span> and a decrease in visual acuity.</p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="rpm1103906a9c0-72c4-11e1-b0c4-0800200c9a66"></a><a name="section-9"></a><p></p>
<h1>11.  DESCRIPTION</h1>
<p class="First">Ocriplasmin is a recombinant truncated form of human plasmin with a molecular weight of 27.2 kDa produced by recombinant DNA technology in a <span class="Italics">Pichia pastoris</span> expression system. </p>
<p>JETREA is a sterile, clear and colorless solution with no preservatives in a single-use glass vial containing 0.5 mg ocriplasmin in 0.2 mL solution for intravitreal injection after dilution.</p>
<p>Each vial contains 0.5 mg ocriplasmin (active) and 0.21 mg citric acid, 0.75 mg mannitol, sodium hydroxide (for pH adjustment) and water for injection. The pH of the solution is 3.1.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="rpm1203906a9c1-72c4-11e1-b0c4-0800200c9a66"></a><a name="section-10"></a><p></p>
<h1>12.  CLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="43679-0">
<a name="rpm1213906a9c2-72c4-11e1-b0c4-0800200c9a66"></a><a name="section-10.1"></a><p></p>
<h2>12.1.  Mechanism of Action</h2>
<p class="First">Ocriplasmin has proteolytic activity against protein components of the vitreous body and the vitreoretinal interface (VRI) (e.g. laminin, fibronectin and collagen), thereby dissolving the protein matrix responsible for the vitreomacular <span class="product-label-link" type="condition" conceptid="4175338" conceptname="Adhesion">adhesion</span> (VMA).</p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="rpm1233906a9c8-72c4-11e1-b0c4-0800200c9a66"></a><a name="section-10.2"></a><p></p>
<h2>12.3.  Pharmacokinetics</h2>
<p class="First">The intravitreal pharmacokinetics of ocriplasmin were determined in a clinical study in patients scheduled for vitrectomy where 0.125 mg ocriplasmin (corresponding to an average concentration of 29 mcg ocriplasmin per mL vitreous volume [approximately 4.3 mL/eye]) was administered as a single intravitreal dose at different time points prior to vitrectomy. The mean ocriplasmin activity levels decreased with time from injection to time of sampling as illustrated in Table 1, according to a second order kinetic process. At 24 hours post injection the levels in the vitreous were below 3% of the theoretical concentration reached immediately after injection.</p>
<p>Because of the small dose administered (0.125 mg), detectable levels of ocriplasmin in systemic circulation are not expected after intravitreal injection.</p>
<p><span class="Bold">Table 1: Mean Ocriplasmin Activity Levels in Vitreous Samples after Intravitreal Injection of 0.125 mg Ocriplasmin</span></p>
<table>
<tfoot>
<tr class="First"><td colspan="6">
<span class="Sup">a</span> 2 subjects below lower limit of detection, other 2 subjects at 0.88 and 0.57 mcg/mL</td></tr>
<tr class="Last"><td colspan="6">
<span class="Sup">b</span> Lower limit of detection</td></tr>
</tfoot>
<tbody class="Headless">
<tr class="First">
<td>
<span class="Bold">Time post-injection</span><br>
												(subjects)</td>
<td align="center">
<span class="Bold">5-30min</span><br>
											               (n=8)</td>
<td align="center">
<span class="Bold">31-60min</span><br>
												(n=8)</td>
<td align="center">
<span class="Bold">2-4hours</span><br>
												(n=8)</td>
<td align="center">
<span class="Bold">24hr ± 2hr</span><br>
												(n=4)</td>
<td align="center">
<span class="Bold">7days ± 1day</span><br>
												(n=4)</td>
</tr>
<tr class="Last">
<td>Mean ± SD<br>
												Ocriplasmin levels<br>
												(mcg/mL)</td>
<td align="center">12 ±7.6</td>
<td align="center">8.1 ±5.2</td>
<td align="center">2.6 ±1.6</td>
<td align="center">0.5 ±0.3<span class="Sup">a</span>
</td>
<td align="center">&lt;0.27<span class="Sup">b</span>
</td>
</tr>
</tbody>
</table>
<p>Ocriplasmin enters the endogenous protein catabolism pathway through which it is rapidly inactivated via its interactions with protease inhibitor α2-antiplasmin or α2-macroglobulin.</p>
</div>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="rpm1303906a9c4-72c4-11e1-b0c4-0800200c9a66"></a><a name="section-11"></a><p></p>
<h1>13.  NONCLINICAL TOXICOLOGY</h1>
<div class="Section" data-sectionCode="34083-6">
<a name="rpm1303906a9c3-72c4-11e1-b0c4-0800200c9a66"></a><a name="section-11.1"></a><p></p>
<h2>13.1.  Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First">No carcinogenicity, mutagenicity or reproductive and developmental toxicity studies were conducted with ocriplasmin.</p>
</div>
<div class="Section" data-sectionCode="34091-9">
<a name="rpm1323906a9c5-72c4-11e1-b0c4-0800200c9a66"></a><a name="section-11.2"></a><p></p>
<h2>13.2.  Animal Toxicology and/or Pharmacology</h2>
<p class="First">The ocular toxicity of ocriplasmin after a single intravitreal dose has been evaluated in rabbits, monkeys and minipigs. Ocriplasmin induced an inflammatory response and transient ERG changes in rabbits and monkeys, which tended to resolve over time. Lens <span class="product-label-link" type="condition" conceptid="72468" conceptname="Open dislocation of jaw">subluxation</span> was observed in the 3 species at ocriplasmin concentrations in the vitreous at or above 41 mcg/mL, a concentration 1.4-fold above the intended clinical concentration in the vitreous of 29 mcg/mL. <span class="product-label-link" type="condition" conceptid="433778" conceptname="Orbital hemorrhage">Intraocular hemorrhage</span> was observed in rabbits and monkeys.</p>
<p>A second intravitreal administration of ocriplasmin (28 days apart) in monkeys at doses of 75 mcg/eye (41 mcg/mL vitreous) or 125 mcg/eye (68 mcg/mL vitreous) was associated with lens <span class="product-label-link" type="condition" conceptid="72468" conceptname="Open dislocation of jaw">subluxation</span> in all ocriplasmin treated eyes. Sustained increases in IOP occurred in two animals with lens <span class="product-label-link" type="condition" conceptid="72468" conceptname="Open dislocation of jaw">subluxation</span>. Microscopic findings in the eye included vitreous liquefaction, degeneration/disruption of the hyaloideocapsular ligament (with loss of ciliary zonular fibers), lens degeneration, mononuclear cell infiltration of the vitreous, and vacuolation of the retinal inner nuclear cell layer. These doses are 1.4-fold and 2.3-fold the intended clinical concentration in the vitreous of 29 mcg/mL, respectively.</p>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="rpm1403906a9c6-72c4-11e1-b0c4-0800200c9a66"></a><a name="section-12"></a><p></p>
<h1>14.  CLINICAL STUDIES</h1>
<p class="First">The efficacy and safety of JETREA was demonstrated in two multicenter, randomized, double masked, vehicle-controlled, 6 month studies in patients with symptomatic vitreomacular <span class="product-label-link" type="condition" conceptid="4175338" conceptname="Adhesion">adhesion</span> (VMA). A total of 652 patients (JETREA 464, vehicle 188) were randomized in these 2 studies. Randomization was 2:1 (JETREA:vehicle) in Study 1 and 3:1 in Study 2.</p>
<p>Patients were treated with a single injection of JETREA or vehicle. In both of the studies, the proportion of patients who achieved VMA resolution at Day 28 (i.e., achieved success on the primary endpoint) was significantly higher in the ocriplasmin group compared with the vehicle group through Month 6 (Table 2 and Figure 7).</p>
<p><span class="Bold">Table 2: Proportion of Patients with VMA Resolution in the Study Eye (Study 1,<br>
							Study 2: Full Analysis Set)</span></p>
<table width="60%"><tbody class="Headless">
<tr class="First">
<td></td>
<td align="center" colspan="3"><span class="Bold">Study 1</span></td>
<td align="center" colspan="3"><span class="Bold">Study 2</span></td>
</tr>
<tr>
<td></td>
<td align="center"><span class="Bold">Vehicle<br>
										N=107</span></td>
<td align="center"><span class="Bold">JETREA<br>
										N=219</span></td>
<td align="center"><span class="Bold">Difference<br>
										(95% CI)
									</span></td>
<td align="center"><span class="Bold">Vehicle<br>
										N=81
									</span></td>
<td align="center"><span class="Bold">JETREA<br>
										N=245
									</span></td>
<td align="center"><span class="Bold">Difference<br>
										(95% CI)
									</span></td>
</tr>
<tr>
<td></td>
<td align="center"><span class="Bold">n (%)</span></td>
<td align="center"><span class="Bold">n (%)</span></td>
<td></td>
<td><span class="Bold">n (%)</span></td>
<td align="center"><span class="Bold">n (%)</span></td>
<td></td>
</tr>
<tr>
<td><span class="Bold">Day 7</span></td>
<td align="center">8 (7.5)</td>
<td align="center">54 (24.7)</td>
<td align="center">17.2 (9.6, 24.8)</td>
<td align="center">1 (1.2)</td>
<td align="center">36 (14.7)</td>
<td align="center">13.5 (8.4, 18.5)</td>
</tr>
<tr>
<td><span class="Bold">Day 14</span></td>
<td align="center">12 (11.2)</td>
<td align="center">57 (26.0)</td>
<td align="center">14.8 (6.5, 23.2)</td>
<td align="center">1 (1.2)</td>
<td align="center">44 (18.0)</td>
<td align="center">16.7 (11.4, 22.1)</td>
</tr>
<tr>
<td><span class="Bold">Day 28</span></td>
<td align="center">14 (13.1)</td>
<td align="center">61 (27.9)</td>
<td align="center">14.8 (6.0, 23.5)</td>
<td align="center">5 (6.2)</td>
<td align="center">62 (25.3)</td>
<td align="center">19.1 (11.6, 26.7)</td>
</tr>
<tr>
<td><span class="Bold">Month 3</span></td>
<td align="center">16 (15.0)</td>
<td align="center">58 (26.5)</td>
<td align="center">11.5 (2.6, 20.5)</td>
<td align="center">7 (8.6)</td>
<td align="center">62 (25.3)</td>
<td align="center">16.7 (8.5, 24.9)</td>
</tr>
<tr class="Last">
<td><span class="Bold">Month 6</span></td>
<td align="center">15 (14.0)</td>
<td align="center">60 (27.4)</td>
<td align="center">13.4 (4.5, 22.2)</td>
<td align="center">10 (12.3)</td>
<td align="center">65 (26.5)</td>
<td align="center">14.2 (5.1, 23.2)</td>
</tr>
</tbody></table>
<p><span class="Bold">Figure 7: Proportion of Patients with VMA Resolution in the Study Eye (Study 1 and<br> Study 2)</span></p>
<p><img alt="VMA Resolution" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=390682b7-72c4-11e1-b0c4-0800200c9a66&amp;name=jetrea-figure-7.jpg"></p>
<p>Total <span class="product-label-link" type="condition" conceptid="4088110" conceptname="Posterior vitreous detachment">posterior vitreous detachment</span> (PVD) induction in symptomatic vitreomacular <span class="product-label-link" type="condition" conceptid="4175338" conceptname="Adhesion">adhesion</span> patients was evaluated by B-scan ultrasound. A statistically significantly higher percentage of JETREA treated patients achieved total PVD at Day 28 compared to vehicle treated patients in Study 1 (16% vs. 6%; p=0.014) and in Study 2 (11% vs. 0%; p&lt;0.01).</p>
<p>The number of patients with at least 3 lines increase in visual acuity was numerically higher in the ocriplasmin group compared to vehicle in both trials, however, the number of patients with at least a 3 lines decrease in visual acuity was also higher in the ocriplasmin group in one of the studies (Table 3 and Figure 8).</p>
<p><span class="Bold">Table 3:	Categorical Change from Baseline in BCVA at Month 6, Irrespective of <br>Vitrectomy (Study 1 and Study 2)</span></p>
<table width="60%"><tbody class="Headless">
<tr class="First">
<td></td>
<td align="center" colspan="3"><span class="Bold">Study 1</span></td>
<td align="center" colspan="3"><span class="Bold">Study 2</span></td>
</tr>
<tr>
<td></td>
<td>JETREA<br> N=219</td>
<td>Vehicle<br> N=107</td>
<td>Difference<br> (95% CI)</td>
<td>JETREA<br> N=245</td>
<td>Vehicle<br> N=81</td>
<td>Difference<br> (95% CI)</td>
</tr>
<tr><td colspan="7"><span class="Bold">≥3 line Improvement in BCVA</span></td></tr>
<tr>
<td>Month 6</td>
<td>28 (12.8%)</td>
<td>9 (8.4%)</td>
<td>4.4 (-2.5, 11.2)</td>
<td>29 (11.8%)</td>
<td>3 (3.8%)</td>
<td>8.1 (2.3, 13.9)</td>
</tr>
<tr><td colspan="7"><span class="Bold">&gt;3 line Worsening in BCVA</span></td></tr>
<tr class="Last">
<td>Month 6</td>
<td>16 (7.3%)</td>
<td>2 (1.9%)</td>
<td>5.4 (1.1, 9.7)</td>
<td>10 (4.1%)</td>
<td>4 (5.0%)</td>
<td>-0.9 (-6.3, 4.5)</td>
</tr>
</tbody></table>
<p><span class="Bold">Figure 8: Percentage of Patients with Gain or Loss of ≥ 3 Lines of BCVA at Protocol- <br>
							Specified Visits</span></p>
<p><img alt="FTMH Closure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=390682b7-72c4-11e1-b0c4-0800200c9a66&amp;name=jetrea-figure-8.jpg"></p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="rpm1603906a9c7-72c4-11e1-b0c4-0800200c9a66"></a><a name="section-13"></a><p></p>
<h1>16.  HOW SUPPLIED/STORAGE AND HANDLING</h1>
<p class="First">Each vial of JETREA contains 0.5 mg ocriplasmin in 0.2 mL citric-buffered solution (2.5 mg/mL). JETREA is supplied in a 2 mL glass vial with a latex free rubber stopper. Vials are for single use only.</p>
<p>NDC 24856-001-00</p>
<div class="Section" data-sectionCode="44425-7">
<a name="rpmstorage3906a9c9-72c4-11e1-b0c4-0800200c9a66"></a><a name="section-13.1"></a><p></p>
<p class="First"><span class="Bold">Storage</span></p>
<p>Store frozen at or below -4°F (-20°C). Protect the vials from light by storing in the original package until time of use.</p>
</div>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="rpm1703906a9ca-72c4-11e1-b0c4-0800200c9a66"></a><a name="section-14"></a><p></p>
<h1>17.  PATIENT COUNSELING INFORMATION</h1>
<p class="First">In the days following JETREA administration, patients are at risk of developing intraocular <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span>/<span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>. Advise patients to seek immediate care from an ophthalmologist if the eye becomes red, sensitive to light, painful, or develops a change in vision <span class="Italics">[see Warnings and Precautions <a href="#rpm052390682c5-72c4-11e1-b0c4-0800200c9a66">(5.2)</a>]</span>.</p>
<p>Patients may experience temporary <span class="product-label-link" type="condition" conceptid="373786" conceptname="Abnormal vision">visual impairment</span> after receiving an intravitreal injection of JETREA <span class="Italics">[see Warnings and Precautions <a href="#rpm051390682c3-72c4-11e1-b0c4-0800200c9a66">(5.1)</a>].</span> Advise patients to not drive or operate heavy machinery until this <span class="product-label-link" type="condition" conceptid="373786" conceptname="Abnormal vision">visual impairment</span> has resolved. If <span class="product-label-link" type="condition" conceptid="373786" conceptname="Abnormal vision">visual impairment</span> persists or decreases further, advise patients to seek care from an ophthalmologist.</p>
<p>Manufactured for:</p>
<p>ThromboGenics, Inc.</p>
<p>101 Wood Avenue South, Suite 610</p>
<p>Iselin, NJ 08830</p>
<br><br><p>U.S. License Number: 1866</p>
<p>©2012, ThromboGenics, Inc. All rights reserved.</p>
<p>Revised September 2015</p>
<p>Initial U.S. Approval: 2012</p>
<p>ThromboGenics U.S. patents: 7,445,775; 7,547,435; 7,914,783 and other pending patents.</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="rpmvial3906a9cb-72c4-11e1-b0c4-0800200c9a66"></a><a name="section-15"></a><p></p>
<p class="First"><span class="Bold">Package Label - Principal Display Panel - JETREA - Vial</span></p>
<p><img alt="Package Label - Principal Display Panel - JETREA - Vial" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=390682b7-72c4-11e1-b0c4-0800200c9a66&amp;name=jetrea-figure-10.jpg"></p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="rpmcarton3906a9cc-72c4-11e1-b0c4-0800200c9a66"></a><a name="section-16"></a><p></p>
<p class="First"><span class="Bold">Package Label - Principal Display Panel - JETREA - Carton</span></p>
<p><img alt="Package Label - Principal Display Panel - JETREA - Carton" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=390682b7-72c4-11e1-b0c4-0800200c9a66&amp;name=jetrea-figure-9.jpg"></p>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>JETREA 		
					</strong><br><span class="contentTableReg">ocriplasmin injection, solution</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:24856-001</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">INTRAVITREAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>OCRIPLASMIN</strong> (OCRIPLASMIN) </td>
<td class="formItem">OCRIPLASMIN</td>
<td class="formItem">2.5 mg  in 1 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CITRIC ACID MONOHYDRATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>MANNITOL</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SODIUM HYDROXIDE</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:24856-001-00</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">0.2 mL in 1 VIAL, SINGLE-USE; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">BLA</td>
<td class="formItem">BLA125422</td>
<td class="formItem">10/31/2012</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>ThromboGenics Inc.
							(133263215)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Fujifilm Diosynth Biotechnologies UK Ltd</td>
<td class="formItem"></td>
<td class="formItem">778997119</td>
<td class="formItem">API MANUFACTURE(24856-001)</td>
</tr>
</table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Patheon UK Limited</td>
<td class="formItem"></td>
<td class="formItem">237710418</td>
<td class="formItem">LABEL(24856-001), MANUFACTURE(24856-001), PACK(24856-001)</td>
</tr>
</table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Patheon Italia S.P.A</td>
<td class="formItem"></td>
<td class="formItem">434078638</td>
<td class="formItem">LABEL(24856-001), MANUFACTURE(24856-001), PACK(24856-001)</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 9/2015<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>89cc897d-986b-40cb-82ba-7ddd7d070410</div>
<div>Set id: 390682b7-72c4-11e1-b0c4-0800200c9a66</div>
<div>Version: 6</div>
<div>Effective Time: 20150916</div>
</div>
</div> <div class="DistributorName">ThromboGenics Inc.</div></p>
</body></html>
